Citations

Showing 10 of 108036 citations.

Burnout and Alcohol Abuse/Dependence Among U.S. Medical Students
Jackson, Eric R., Hasan, Omar , Satele, Daniel , Shanafelt, Tait D. , Dyrbye, Liselotte N.

Mayo Clinic

Academic Medicine | March 2, 2016 | Volume: 91 | Issue: 9 | Pages: 1251-1256

10.1097/acm.0000000000001138 | PMID 26934693 Get It

Purpose To explore the relationship between alcohol abuse/dependence with burnout and other forms of distress among a national cohort of medical students. Method In 2012, the authors completed a national survey of medical students from the American Medical Association’s Physician Masterfile containing validated items assessing alcohol abuse/dependence, burnout, depression, suicidality, quality of life (QOL), and fatigue. Descriptive and comparative statistical analyses were computed, including chi-square and multivariate logistic regression, to determine relationships between variables. Results Of the 12,500 students, 4,402 (35.2%) responded. Of these, 1,411 (32.4%) met diagnostic criteria for alcohol abuse/dependence. Students who were burned out ( P = .01), depressed ( P = .01), or reported low mental ( P =.03) or emotional ( P = .016) QOL were more likely to have alcohol abuse/dependence. Emotional exhaustion and depersonalization domains of burnout were strongly associated with alcohol abuse/dependence. On multivariate analysis, burnout (OR 1.20; 95% CI 1.05–1.37; P < .01), having $50,000 to $100,000 (OR 1.21 versus < $50,000; CI 1.02–1.44; P < .05) or > $100,000 (OR 1.27 versus < $50,000; CI 1.08–1.48; P < .01) of educational debt, being unmarried (OR 1.89; CI 1.57–2.27; P < .001), and being younger (for every five years, OR 1.15; CI 1.02–1.28; P = .01) were independently associated with increased risk for alcohol abuse/dependence. Conclusions Burnout was strongly related to alcohol abuse/dependence among sampled medical students and increased educational debt predicted a higher risk. A multifaceted approach addressing burnout, medical education costs, and alcohol use is needed.
Important Skills for Internship and the Fourth-Year Medical School Courses to Acquire Them: A National Survey of Internal Medicine Residents
Pereira, Anne G. , Harrell, Heather, Weissman, Arlene, Smith, Cynthia D. , Dupras, Denise M. , Kane, Gregory C.

Mayo Clinic

Academic Medicine | March 2, 2016 | Volume: 91 | Issue: 6 | Pages: 821-826

10.1097/acm.0000000000001134 | PMID 26934691 Get It

Purpose To obtain feedback from internal medicine residents, a key stakeholder group, regarding both the skills needed for internship and the fourth-year medical school courses that prepared them for residency. This feedback could inform fourth-year curriculum redesign efforts. Method All internal medicine residents taking the 2013–2014 Internal Medicine In-Training Examination were asked to rank the importance of learning 10 predefined skills prior to internship and to use a dropdown menu of 11 common fourth-year courses to rank the 3 most helpful in preparing for internship. The predefined skills were chosen based on a review of the literature, a national subinternship curriculum, and expert consensus. Chi-square statistics were used to test for differences in responses between training levels. Results Of the 24,820 internal medicine residents who completed the exam, 20,484 (83%) completed the survey, had complete identification numbers, and consented to have their responses used for research. The three skills most frequently rated as very important were identifying when to seek additional help and expertise, prioritizing clinical tasks and managing time efficiently, and communicating with other providers around care transitions. The subinternship/acting internship was most often selected as being the most helpful course in preparing for internship. Conclusions These findings indicate which skills and fourth-year medical school courses internal medicine residents found most helpful in preparing for internship and confirm the findings of prior studies highlighting the perceived value of subinternships. Internal medicine residents and medical educators agree on the skills students should learn prior to internship.
Analytical Insights from Patient Narratives: The Next Step for Better Patient Experience
Cognetta-Rieke, Cheristi, Güney, Senem

Mayo Clinic

Journal of Patient Experience | March 2, 2016 | Volume: 1 | Issue: 1 | Pages: 20-22

10.1177/237437431400100105 | PMID 28725797 Get It

Cholesterol Granuloma Development following Temporal Bone Surgery
Sweeney, Alex D. , Osetinsky, L. Mariel, Hunter, Jacob B. , Haynes, David S. , Carlson, Matthew L. , Hunter, Jacob B

Mayo Clinic

Otolaryngology–Head and Neck Surgery | March 1, 2016 | Volume: 154 | Issue: 6 | Pages: 1115-1120

10.1177/0194599816630954 | PMID 26932968 Get It

ObjectiveTo describe the clinical presentation and management of patients with cholesterol granulomas (CGs) that develop following temporal bone surgery.Study DesignCase series with chart review.SettingTwo independent tertiary academic referral centers.Subjects and MethodsA multicenter retrospective review was performed to identify all patients between 2001 and 2014 who were diagnosed with a CG that developed following temporal bone surgery. Patients with a history of idiopathic petrous apex CGs were excluded, as were those with <6 months of follow‐up after diagnosis. Demographic and clinical data were recorded at presentation, and the main outcome measure was symptom evolution over time.ResultsA total of 20 patients met inclusion criteria (median age, 55.0 years; 70.0% female), and their cases were analyzed. Diagnosis was made, on average, 149.5 months (median, 94.5; range, 13.0‐480.0) following a temporal bone operation, which was for chronic ear disease in 75.0% of cases. The most common presenting symptoms were otalgia (55.0%) and otorrhea (40.0%). In patients initially managed with observation, 71.4% required no surgical intervention through a mean of 56.8 months (median, 30; range, 12.0‐178.0) of follow‐up. For those who initially underwent surgical excision, durable symptom relief was achieved in 66.7% of cases.ConclusionPostoperative CG formation in the temporal bone is a rare occurrence that can be encountered years following surgery. The present study suggests that conservative management can be appropriate for many cases in which patients are relatively asymptomatic.
Investigating the Metabolic Syndrome
Zhang, Xin , Lerman, Lilach O.

Mayo Clinic

Toxicologic Pathology | March 1, 2016 | Volume: 44 | Issue: 3 | Pages: 358-366

10.1177/0192623316630835 | PMID 26933085 Get It

The metabolic syndrome (MetS), a cluster of dyslipidemia, hypertension, and diabetes and an important contributor to cardiovascular morbidity and mortality, occurs in nearly 35% of adults and 50% of the aging population in the United States. However, the underlying mechanisms by which MetS orchestrates and amplifies cardiovascular events remain elusive. Furthermore, traditional therapeutic strategies addressing lifestyle modifications and individual components of MetS are often unsuccessful in decreasing morbidity due to MetS. The availability of an adequate experimental platform that mimics the complexity of MetS may allow development of novel management techniques. Swine models, including domestic pigs and minipigs, have made important contributions to our understanding of many aspects of MetS. Given their similarity to human anatomy and physiology, those models may have significant predictive power for elucidating the pathophysiology of MetS in a manner applicable to humans. Moreover, experimental maneuvers and drugs can be tested in these preclinical models before application in patients with MetS. This review highlights the utility of the pig as an animal model for metabolic disorders, which may play a crucial role in novel drug development to optimize management of MetS.
Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes
Hinshaw, Ling , Schiavon, Michele , Dadlani, Vikash, Mallad, Ashwini , Man, Chiara Dalla , Bharucha, Adil E. , Basu, Rita , Geske, Jennifer R. , Carter, Rickey E. , Basu, Ananda , Kudva, Yogish C. , Dalla Man, Chiara, Bharucha, Adil, Cobelli, Claudio , Dalla Man, Chiara , Carter, Rickey E , Geske, Jennifer , Schiavon, Michele

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 1, 2016 | Volume: 101 | Issue: 5 | Pages: 1954-1962

10.1210/jc.2015-3952 | PMID 26930181 Get It

Abstract Context: Early postprandial hyperglycemia and delayed hypoglycemia remain major problems in current management of type 1 diabetes (T1D). Objective: Our objective was to investigate the effects of pramlintide, known to suppress glucagon and delay gastric emptying, on postprandial glucose fluxes in T1D. Design: This was a single-center, inpatient, randomized, crossover study. Patients: Twelve patients with T1D who completed the study were analyzed. Interventions: Subjects were studied on two occasions with or without pramlintide. Triple tracer mixed-meal method and oral minimal model were used to estimate postprandial glucose turnover and insulin sensitivity (SI). Integrated liver insulin sensitivity was calculated based on glucose turnover. Plasma glucagon and insulin were measured. Main Outcome Measure: Glucose turnover and SI were the main outcome measures. Results: With pramlintide, 2-hour postprandial glucose, insulin, glucagon, glucose turnover, and SI indices showed: plasma glucose excursions were reduced (difference in incremental area under the curve [iAUC], 444.0 mMmin, P = .0003); plasma insulin concentrations were lower (difference in iAUC, 7642.0 pMmin; P = .0099); plasma glucagon excursions were lower (difference in iAUC, 1730.6 pg/mlmin; P = .0147); meal rate of glucose appearance was lower (difference in iAUC: 1196.2 μM/kg fat free mass [FFM]; P = .0316), endogenous glucose production was not different (difference in iAUC: −105.5 μM/kg FFM; P = .5842), rate of glucose disappearance was lower (difference in iAUC: 1494.2 μM/kg FFM; P = .0083). SI and liver insulin sensitivity were not different between study visits (P &gt; .05). Conclusions: Inhibition of glucagon and gastric emptying delaying reduced 2-hour prandial glucose excursions in T1D by delaying meal rate of glucose appearance.
Clinical course of patients with incidental finding of 20q‐ in the bone marrow without a morphologic evidence of myeloid neoplasm
Jawad, Majd, Oliveira, Jennifer L. , Hoyer, James D., Hook, C. Christopher , Herrick, Jennifer L. , Jawad, Majd D, Shi, Min , Go, Ronald S.

Mayo Clinic

American Journal of Hematology | March 1, 2016 | Volume: 91 | Issue: 6 | Pages: 556-559

10.1002/ajh.24347 | PMID 26928533 Get It

Deletion of the long arm of chromosome 20 (20q‐) is a frequent finding in bone marrow karyotypes, mainly associated with myeloid neoplasms (MNs). Its clinical significance in the setting of normal bone marrow morphology is unclear. We described the clinical characteristics, cytogenetic findings, and outcome of 102 such patients seen at our institution from 2000‐2014. Their median age was 66 years. The indication for bone marrow biopsy was either unexplained cytopenias (48%) or hematologic cancer staging/reevaluation (52%). In 88 (86%) patients, 20q‐ was an isolated finding. Thirty‐nine (38%) patients previously received chemotherapy and 88 (86%) had cytopenias at the time of 20q‐ finding. After a median of 35 months, 12 (13%) patients developed MNs: 10 myelodysplastic syndromes, one acute myeloid leukemia and one myeloproliferative neoplasm. None of 14 patients with normal blood counts, but 7 of 35 (20%) with mild cytopenias, and 5 of 53 (9%) with moderate/severe cytopenias developed MNs. We did not find an association between the number of metaphases with 20q‐ and the development of MN. The incidental finding of 20q‐ in the bone marrow generally does not portend an early stage MN. Particularly, those without cytopenias at the time of diagnosis may have a good prognosis. Am. J. Hematol. 91:556–559, 2016. © 2016 Wiley Periodicals, Inc.
Evidence on Use of Neuroimaging for Surgical Treatment of Temporal Lobe Epilepsy
Jones, Amy L., Cascino, Gregory D.

Mayo Clinic

JAMA Neurology | March 1, 2016 | Volume: 73 | Issue: 4 | Pages: 464

10.1001/jamaneurol.2015.4996 | PMID 26926529 Get It

Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment
Schak, Kathryn M. , Voort, Jennifer L. Vande , Johnson, Emily K. , Kung, Simon , Leung, Jonathan G. , Rasmussen, Keith G., Palmer, Brian A. , Frye, Mark A. , Vande Voort, Jennifer L., Leung, Jonathan G

Mayo Clinic

American Journal of Psychiatry | March 1, 2016 | Volume: 173 | Issue: 3 | Pages: 215-218

10.1176/appi.ajp.2015.15081082 | PMID 26926127 Get It

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
Petrylak, Daniel P. , Tagawa, Scott T. , Eisen, Andrea , Canil, Christina , Burke, John M. , Shaffer, David R. , Pan, Chong‐Xian, Aragon‐Ching, Jeanny B. , Tang, Shande, Zhang, Hui , Cavanaugh, Christopher , Gao, Ling , Walgren, Richard A., Kohli, Manish , Spira, Alexander, Yu, Evan Y., Shaffer, David, Kim, Jenny J, Aragon-Ching, Jeanny B, Quinn, David I, Vogelzang, Nicholas J. , Cavanaugh, Christopher T, Kauh, John S, Chi, Kim N, Sridhar, Srikala S , Spira, Alexander I. , Yu, Evan Y , Kim, Jaeyeon , Quinn, David I , Kauh, John Sae Wook , N., Kim , Tagawa, Scott T , Eisen, Andrea

Mayo Clinic

Journal of Clinical Oncology | March 1, 2016 | Volume: 34 | Issue: 13 | Pages: 1500-1509

10.1200/jco.2015.65.0218 | PMID 26926681 Get It

Purpose This trial assessed the efficacy and safety of docetaxel monotherapy or docetaxel in combination with ramucirumab (vascular endothelial growth factor receptor 2 antibody) or icrucumab (vascular endothelial growth factor receptor 1 antibody) after progression during or within 12 months of platinum-based regimens for patients with locally advanced or metastatic urothelial carcinoma. Patients and Methods Patients were randomly assigned (1:1:1) to receive docetaxel 75 mg/m2 intravenously (IV) on day 1 of a 3-week cycle (arm A), docetaxel 75 mg/m2 IV plus ramucirumab 10 mg/kg IV on day 1 of a 3-week cycle (arm B), or docetaxel 75 mg/m2 IV on day 1 plus icrucumab 12 mg/kg IV on days 1 and 8 of a 3-week cycle (arm C). Treatment continued until disease progression or unacceptable toxicity. The primary end point was investigator-assessed progression-free survival (PFS). Results A total of 140 patients were randomly assigned and treated in arms A (n = 45), B (n = 46), or C (n = 49). PFS was significantly longer in arm B compared with arm A (median, 5.4 months; 95% CI, 3.1 to 6.9 months v 2.8 months; 95% CI, 1.9 to 3.6 months; stratified hazard ratio, 0.389; 95% CI, 0.235 to 0.643; P = .0002). Arm C did not experience improved PFS compared with arm A (1.6 months; 95% CI, 1.4 to 2.9; stratified hazard ratio, 0.863; 95% CI, 0.550 to 1.357; P = .5053). The most common grade 3 or worse adverse events (arms A, B, and C) were neutropenia (36%, 33%, and 39%), fatigue (13%, 30%, and 20%), febrile neutropenia (13%, 17%, and 6.1%), and anemia (6.7%, 13%, and 14%, respectively). Conclusion The addition of ramucirumab to docetaxel met the prespecified efficacy end point for prolonging PFS in patients with locally advanced or metastatic urothelial carcinoma receiving second-line treatment and warrants further investigation in the phase III setting.